Prosecution Insights
Last updated: May 29, 2026
Application No. 17/759,568

METHODS OF CONTROLLING OR PREVENTING PANAMA DISEASE IN BANANA PLANTS

Non-Final OA §112
Filed
Jul 27, 2022
Priority
Jan 30, 2020 — EU 20154534.0 +1 more
Examiner
ALLEY, GENEVIEVE S
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta Crop Protection AG
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
432 granted / 719 resolved
At TC average
Strong +50% interview lift
Without
With
+49.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
50 currently pending
Career history
761
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
66.8%
+26.8% vs TC avg
§102
6.7%
-33.3% vs TC avg
§112
2.6%
-37.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 719 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims No new claim set was filed. Amended claims Newly canceled claims Newly added claims Previously canceled claims 3-11, 14-16 Previously withdrawn claims Claims under instant examination 1-2, 12-13, 17-20 Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/16/26 has been entered. Information Disclosure Statement The information disclosure statement (IDS) submitted on 4/16/26 has been considered by the examiner. New Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-2, 12-13 and 17-20 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-2, 12-13 and 17-20 are unclear as claim 1 recites the limitation "the phytopathogenic microorganism Fusarium oxysporum f.sp (forma specialis) cubense (Foc)" in line 2. There is insufficient antecedent basis for this limitation in the claim (emphasis added). Therefore, it is unclear what this limitation refers to and how to interpret the claim. The Examiner suggests replacing “the” with “a” in order to obviate the instant rejection. Claims depending from rejected claims have also been rejected because they incorporate all of the limitations of the claims from which they depend, but fail to resolve the indefinite concerns outlined above. New Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 2 recites “wherein the phytopathogenic microorganism is Fusarium odoratissimum” and is dependent on claim 1. However, this species is outside of the scope of claim 1. Claim 1 requires the phytopathogenic microorganism to be Fusarium oxysporum f.sp (forma specialis) cubense, which has the following scientific classification: Fusarium genus, F. oxysporum species, and F. o. f.sp. cubense forma specialis, whereas claim 2 requires the phytopathogenic microorganism to be Fusarium odoratissimum, which has the following scientific classification: Fusarium genus and F. odoratissimum species. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to GENEVIEVE S ALLEY whose telephone number is (571)270-1111. The examiner can normally be reached on Monday-Friday 8:00-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GENEVIEVE S ALLEY/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Jul 27, 2022
Application Filed
Feb 17, 2026
Response after Non-Final Action
Apr 16, 2026
Request for Continued Examination
Apr 20, 2026
Response after Non-Final Action
Apr 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636289
LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF
3y 3m to grant Granted May 26, 2026
Patent 12629366
PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS
2y 6m to grant Granted May 19, 2026
Patent 12629377
LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF
1y 10m to grant Granted May 19, 2026
Patent 12616699
OPHTHALMIC FORMULATIONS OF METHOTREXATE
4y 1m to grant Granted May 05, 2026
Patent 12605365
LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE
3y 4m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+49.5%)
2y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 719 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month